Scholars Central

Conference abstractPublished 8 Mar 2018

Small molecules RSC001 use in breast cancer model

Authors: Zheng Shuo Jin, Hai Yan Wang

Tsinghua University, China

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

RSC001 is a small molecule we had screened by HTS technology which can recruit chemokine in cells and these molecules belong to kinases inhibitor, serine kinases which are essential for cell proliferation. It can help in cell division and proliferation, the enzyme controlling chromatid segregation in cell cycle. Defects in this segregation can cause genetic instability, a condition which is highly associated with tumorigenesis, several cancer patients have detected higher expression of aurora kinases. The incidence of breast cancer has continued to rise over the last decade and has become the first major cause of cancer deaths in women in developing countries. The current treatment of breast cancer always uses chemotherapy or surgery treatment, experiments show that accurate treatment can be more effective in treating breast cancer and reduce the side effect during treatment. In the preliminary experiments held by Haiyan Wang shows that aurora kinases inhibitor can effectively inhibit tumor development. So, we decided to continue studying the role of the drug in breast cancer treatment, in the animal experiment the result shows that RSC001 can increase the recruit of immune cells around the tumor cells. From this phenomenon we hope we can explore the mechanism of these kinase inhibitor drug induced chemokine, Through the experiment, we noticed that breast cancer cell line 231 which added RSC001 molecule had high expression of chemokine CXCL11 and CXCL10 when STAT3 had low expression. Considering the chemokine activation pathway, we concentrated on JAK-STAT signal pathway and found the relationship between STAT1 and STAT3 and also the regulation of chemokine and autoimmune cell thus to make an immunotherapy of breast cancer. Immunotherapy combined with precision medicine can better solve breast cancer in the future. Recent Publications 1. Huck J J, Zhang M, McDonald A, Bowman D, Hoar K M, Stringer B et al. (2010) MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol. Cancer Res. 8(3):373-384. 2. Salvatore Ulisse (2017) Solid cancer treatment with aurora kinase inhibitors: Towards a personalized medicine. EBioMedicine. 25:18-19. 3. Christian Lis, Stefan Rubner, Martin Roatsch, Angela Berg, Tyler Gilcrest et al. (2017) Development of Erasin: A chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells. 7(1):17390.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalImmunome Research
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Zheng Shuo Jin”
  • BylineArticles whose byline prints “Hai Yan Wang”